

**To: AmeriHealth Caritas Pennsylvania Community HealthChoices
Medical Providers**

Date: August 23, 2018

Subject: Valsartan and Valsartan HCTZ Recall

Summary: The U.S. Food and Drug Administration (FDA) announced a voluntary recall of several medicines containing valsartan following detection of an impurity.

The FDA is alerting health care professionals and patients of a voluntary recall of several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure. This recall is due to an impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled products. NDMA is classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.

For more information, including the specific products that are subject to the recall, please visit www.fda.gov/Safety/Recalls/ucm613729.htm or www.fda.gov → **Safety** (bottom of page) → **Recalls, Market Withdrawals, & Safety Alerts** → **7/13/2018 Major Pharmaceuticals Valsartan tablets**.

Requested actions

- Please work with your patients to find a replacement for their prescription if their pharmacy does not have another manufacturer's valsartan product.
- To access to our searchable formulary for alternatives if needed, please go to: www.amerhealthcaritaschc.com → **Providers** → **Pharmacy Services** → **Searchable Formulary**

Questions?

If you have any questions about this communication, please call PerformRxSM Pharmacy Services at: **1-888-674-8720**.

¹ "Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy," HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C, May 24, 2018, <https://www.hcvguidelines.org/evaluate/monitoring>.

¹ Charles Daniel, "Hepatitis C Treatment and Sustained Virologic Response: Understanding This Hepatitis C 'Cure'," verywellhealth.com, March 26, 2018, <https://www.verywellhealth.com/what-is-a-sustained-virologic-response-or-svr-1760132>.